Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study

• Status: Unknown status
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.

We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.

Details

• Lead Sponsor: Assaf-Harofeh Medical Center
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

1. Diagnosis of Diabetes Mellitus Type II

2. Treatment With Oral hypoglycemics

3. Availability of Baseline and follow up clinical data

Exclusion Criteria:

1. Insulin Therapy at baseline

2. Malignancy